First Generic Alternative to Eliquis® Now Available in Canada
Jul 20, 2022TORONTO, June 20, 2022 /CNW/ - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban™ tablets, Canada's first generic alternative to Eliquis®.
Apotex's apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots. Available in 2.5 mg and 5mg tablets, this product comes in multiple package sizes including 60, 180, and 500 BTL.
"It is with great pride that we launch APO-Apixaban™," said Raymond Shelley, SVP, Commercial Operations, Canada & Rest of World Markets. "Gaining access to a generic option of an important medication like Eliquis® provides patients with more affordable opportunities for the treatment of blood clots."
Anticoagulants, also known as blood thinners, are administered to patients who are at a high risk of getting blood clots, to reduce their chances of developing serious conditions such as strokes and heart attacks. APO-Apixaban™ adds to our anticoagulant portfolio, which currently includes APO-Dabigatran.
We remain committed to bringing more generics to Canadian patients.
About Apotex Inc.
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through vertical integration, Apotex is comprised of multiple divisions and affiliates including Apotex Inc., focused on generics; Apobiologix, a division of Apotex Inc. focused on biosimilars; Aveva, an affiliate of Apotex Inc. fully integrated global developer and manufacturer of complete transdermal solutions; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc. focused on the manufacturing of active pharmaceutical ingredients (API) for Apotex and third parties. For more information visit: www.apotex.com.
Eliquis® is registered trademark owned by Bristol-Myers Squibb Holdings.
APO-Apixaban™ is a trademark owned by Apotex Inc.
APOTEX, APO and Apobiologix are registered trademarks owned by Apotex Inc.
SOURCE Apotex Inc.
For all media inquiries, please contact:
Jordan Berman
Vice-President, Global Corporate Affairs
PH: 416-401-7487
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.